Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical Study

NCT04513301 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Lung Neoplasms

Interventions

DRUG: Sintilimab
RADIATION: Radiotherapy

Sponsor

Shanghai Cancer Hospital, China